NASDAQ NMS - GLOBAL MARKET · KURA
+1.62% · +$0.1900 · Vol 2.0M
Market closed · last close 4:00 PM ET · price as of 19:01:14 ET
Kura Oncology Inc

Kura Oncology Inc

Biotechnology
$11.90
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
KURA
Kura Oncology Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

53/ 100
Veridion Score
NEUTRAL · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is KURA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading KURA catalysts
About Kura Oncology Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2015
Employees
260
Country
US

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$11.78
Day high
$12.25
Day low
$11.67
Previous close
$11.71
52W high
$12.53
-5.03% from high
52W low
$7.40
88% of range
Market cap
$1.1B
EPS
$-3.2000
Beta
1.19
Shares out
89M
Volume
2M
1.28× rel vol
Avg volume
1.6M
VWAP
$11.92
Price history computed in-house
1W
+9.58%
1M
+14.53%
3M
+5.78%
1Y
+55.56%
YTD
+14.53%
SMA 50 $10.47 · above
SMA 200 $9.68 · above
52W position 88%

KURA overview

Veridion Score
53
Registered · 2026-08-21
6 of 6 factors measured
Latest receipt rows
1
Christopher L. Jacobs · Purchase
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around KURA.Congress disclosuresOpen receipt and filing context for KURA.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading KURA Form 4 filings
Public disclosures

Congress activity in KURA

Congress trackerOpen ticker disclosure ledger →
Federal contracts

KURA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KURA in this window.
Lobbying spend

KURA lobbying filings, year to date.

Registered lobbying filings matched to Kura Oncology Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KURA in this window.
Loading news for KURA
Analyst ratings
Sovereign unlock shows live analyst consensus for KURA.
Options
Sovereign unlock shows live options positioning for KURA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.